Skip to content
Inbal Goldshtein, PhD; David M. Steinberg, PhD; Jacob Kuint, MD; Gabriel Chodick, PhD; Yaakov Segal, MD; Shirley Shapiro Ben David, MD; Amir Ben-Tov, Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes. JAMA Pediatrics. 2022 Feb 10.

Importance Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore,
observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization.
Objective To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns.
Design, Setting, and Participants Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated
health care organization in Israel, followed up until October 31, 2021.
Exposure Maternal BNT162b2 mRNA vaccination during pregnancy.
Main Outcomes and Measures Risk ratios (RR) of preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant
death. Stabilized inverse probability weighting was used to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza
immunization status.
Results The cohort included 24 288 eligible newborns (49% female, 96% born at ≥37 weeks’ gestation), of whom 16 697 were exposed (n = 2134 and n = 9364 in the first and
second trimesters, respectively) to maternal vaccination in utero. Median (IQR) follow-up after birth was 126 days (76-179) among exposed and 152 days (88-209) among
unexposed newborns. No substantial differences were observed in preterm birth rates between exposed and unexposed newborns (RR = 0.95; 95% CI, 0.83-1.10) or SGA
(RR = 0.97; 95% CI, 0.87-1.08). No significant differences were observed in the incidence of all-cause neonatal hospitalizations (RR = 0.99; 95% CI, 0.88-1.12), postneonatal
hospitalizations after birth (RR = 0.95; 95% CI, 0.84-1.07), congenital anomalies (RR = 0.69; 95% CI, 0.44-1.04), or infant mortality over the study period (RR = 0.84; 95%
CI, 0.43-1.72).
Conclusions and Relevance This large population-based study found no evident differences between newborns of women who received BNT162b2 mRNA vaccination
during pregnancy, vs those of women who were not vaccinated, and contributes to current evidence in establishing the safety of prenatal vaccine exposure to the newborns.
Interpretation of study findings is limited by the observational design

assignment_turned_in Registrations

Please login to view this page.
Please login to view this page.
Please login to view this page.
No item in the cart
Go shopping!